Bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
phenylacetaldehyde methyl salicylate 2-phenylethanol benzaldehyde benzyl alcohol benzyl acetate methyl-2-methoxy benzoate Although the strongest attractor is phenylacetaldehyde, the cabbage looper is more attracted to a blend of odors than phenylacetaldehyde alone.
== Company history == BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
10 November Dead Men Talk, new dating techniques reveal more about the evolution of man, found from the Skhul and Qafzeh hominins at the Qafzeh cave, and future DNA sequencing methods could reveal from bones how man evolved, it featured Milford H. Wolpoff and Chris Stringer, being similar to the September 1996 edition about Neanderthals; a cave object was thought to be 40,000 years ago, but now was thought to be 100,000 years old; there were two paradigms, one where everyone is from Homo Erectus, and the other where Homo Sapiens evolved exclusively in Africa from Homo Erectus; this theory was from evidence at Border Cave in South Africa, Omo Kibish Formation in Ethiopia, and the Skhul cave; Milford Wolpoff, of the University of Michigan, supported the first multi-regional model; the second Eve theory came from Chris Stringer of the Natural History Museum, who looked at a fossil at Jebel Irhoud, Morocco; new dating techniques were electron spin resonance dating (ESR), deployed by Dr Rainer Grün at the Godwin Laboratory, University of Cambridge, and thermoluminescence dating (TL) which looked at flints that had been heated in primitive fires; a Neanderthal at Kebara Cave was dated at 60,000, with the new dating technique; the two caves, Skhul had homo sapiens, and Tanum Cave had Neanderthals, nearby; Chris Stringer thought that the Neanderthals split 300,000 years ago; the Neanderthal found at Amud Cave had a large brain; Joel Rak of Tel Aviv University believed that Neanderthals were a separate species; geneticist Rebecca L.
=== Distinguishing origins of natural gas === Biogenic, thermogenic and abiotic methane is formed at different temperatures, which can be recorded in clumped isotope compositions of methane. Combined with conventional carbon and hydrogen isotope fingerprints and gas wetness (the abundance of low molecular weight hydrocarbon), methane clumped isotope can be used to identify the origins of methane in different types of natural gas accumulations.
== Pharmacology == Vinblastine is a vinca alkaloid and a chemical analogue of vincristine. It binds tubulin, thereby inhibiting the assembly of microtubules. Vinblastine treatment causes M phase specific cell cycle arrest by disrupting microtubule assembly and proper formation of the mitotic spindle and the kinetochore, each of which are necessary for the separation of chromosomes during anaphase of mitosis. Toxicities include bone marrow suppression (which is dose-limiting), gastrointestinal toxicity, potent vesicant (blister-forming) activity, and extravasation injury (forms deep ulcers). Vinblastine paracrystals may be composed of tightly packed unpolymerized tubulin or microtubules. Vinblastine is reported to be an effective component of certain chemotherapy regimens, particularly when used with bleomycin and methotrexate in VBM chemotherapy for Stage IA or IIA Hodgkin lymphomas. The inclusion of vinblastine allows for lower doses of bleomycin and reduced overall toxicity with larger resting periods between chemotherapy cycles.
Sources: en.wikipedia.org
Many of these forms are initially water-soluble, which is a disadvantage where the material must retain its shape within the body. Stability is achieved by increasing the beta-sheet content, through treatment with methanol or ethanol, exposure to water vapour, mechanical stretching, or controlled heating. Because the same ordered structure governs both strength and the rate of degradation, this step also serves as the principal means of tuning a material's properties.
== Further reading == Zolkepli, Farik (September 26, 2007). "Johor home to world's first bitubale packaging plant - Business News". The Star. Retrieved August 2, 2016. Zolkepli, Farik (September 3, 2007). "Bitumen Bale sets up first bitubale packaging plant - Business News". The Star. Retrieved August 2, 2016.
== Overdose == Overdose in animals produced effects including convulsions, tremor, paralysis, inactivity, extremity erythema, abnormal breathing, cyanosis, ataxia, mydriasis, and injection site reactions. The elimination half-life of sumatriptan in humans is 2.5 hours. The effect of dialysis on sumatriptan levels is unknown. Overdose of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to green, due to the integration of sulfur into the hemoglobin molecule. If sumatriptan is discontinued, the condition reverses within a few weeks.
COS + H2O → CO2 + H2S This conversion is catalyzed in solution by carbonic anhydrase enzymes in plants and mammals. Because of this chemistry, the release of carbonyl sulfide from small organic molecules has been identified as a strategy for delivering hydrogen sulfide, which is gaseous signaling molecule. This compound is found to catalyze the formation of peptides from amino acids. This finding is an extension of the Miller–Urey experiment, and it is suggested that carbonyl sulfide played a significant role in the origin of life. In ecosystem science, are increasingly being used to describe the rate of photosynthesis.
Sources: en.wikipedia.org
Before entering metamorphosis, the larvae expel a transparent glue from their salivary gland through their mouth, which solidifies within a few seconds and fixes them into a substrate. Then the larvae encapsulate in the puparium and undergo a four-day-long metamorphosis (at 25 °C), after which the adults eclose (emerge).
From then on, through to 2016 there was a period of extended stability for the markets, until in April when the large Nucleus marketplace collapsed for unknown reasons, taking escrowed coins with it. On April 28, investigations into the Italian Darknet Community (IDC) forum-based marketplace led to a number of key arrests. In May 2017, the Bloomsfield Market closed after investigations in Slovakia inadvertently led to the arrests of its operators. Later that month, the long-lived Outlaw market closed down citing a major bitcoin cryptocurrency wallet theft; however, speculation remained that it was an exit scam. In July 2017, the markets experienced their largest disruptions since Operation Onymous, when Operation Bayonet culminated in coordinated multinational seizures of both the Hansa and leading AlphaBay markets, sparking worldwide law enforcement investigations. The seizures brought in lots of traffic to other markets making TradeRoute and Dream Market the most popular markets at the time. In October 2017, TradeRoute exit-scammed shortly after being hacked and extorted. In June 2018, the digital security organization Digital Shadows reported that, due to the climate of fear and mistrust after the closure of AlphaBay and Hansa, darknet market activity was switching away from centralized marketplace websites and towards alternatives such as direct chat on Telegram, or decentralized marketplaces like OpenBazaar.
== O == octreotide - odorant receptor - olfaction - olfactory receptor neuron - oligopeptide - oncogene - oncogene protein - oncogene proteins V-abl - oncogenic retroviridae protein - open reading frame - opioid receptor - opsin - optical isomerism - organ (anatomy) - organelle - organic chemistry - organic compound - organic nomenclature - organic reaction - organism - osmosis - osteocalcin - outer hair cell - outline of biochemical techniques - ovalbumin - oxidation - oxidation number - oxidation state - oxidative decarboxylation - oxidative phosphorylation - oxygen - oxytocin - oxytocin receptor
The newest formulation to come out was in 2014 when zohydro, an increased dosage formula of hydrocodone, was released; this is so far the strongest hydrocodone formulation created for pain management, on par with a moderate dose of oxycodone .
== External links == "Pivekimab Sunirine ( Code - C184834 )". EVS Explore. Clinical trial number NCT03386513 for "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN" at ClinicalTrials.gov
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.